Mind Medicine (MNMD) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Mind Medicine (MindMed) Inc. has presented promising results from its Phase 2b study of MM120, a treatment for Generalized Anxiety Disorder (GAD), showing significant efficacy and sustained benefits over 12 weeks from a single dose. The study, showcased at the APA Annual Meeting, demonstrates the drug’s potential to become a new treatment option for GAD, a condition with limited recent advancements in medication.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
